文献速递药物相互作用肝肾功能剂量调整特殊人群用药

非甾体盐皮质激素受体拮抗剂非奈利酮的药代动力学

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone.
PubMed 文献 · Clin Pharmacokinet · 2023-10-24

非奈利酮是选择性非甾体盐皮质激素受体拮抗剂,获批用于2型糖尿病相关慢性肾脏病的心肾保护。本综述总结其药代动力学研究,显示口服生物利用度43.5%,经CYP3A4(90%)和CYP2C8(10%)代谢,中重度肾损伤或中度肝损伤无需按损伤程度调整剂量,但需根据eGFR起始并按血钾和eGFR变化滴定,与强CYP3A4抑制剂合用禁忌。

要点

  • 非奈利酮起始剂量基于eGFR,根据血钾和eGFR下降滴定。
  • 与强CYP3A4抑制剂合用禁忌,应避免强或中度CYP3A4诱导剂。
  • 开始或调整非奈利酮或中/弱CYP3A4抑制剂剂量时需监测血钾。

核心结论

  • 非奈利酮药代动力学呈线性,半衰期2至3小时(剂量范围至20 mg),年龄、性别、体型或种族对全身暴露无相关影响。
  • 中重度肾损伤或中度肝损伤导致非奈利酮AUC增加<40%,本身无需调整剂量,但起始剂量基于eGFR并按血钾和eGFR下降滴定。
  • 非奈利酮为敏感CYP3A4底物,与强CYP3A4抑制剂合用禁忌,应避免强或中度CYP3A4诱导剂。

研究设计与样本

  • 本文为综述,总结多项研究以评估非奈利酮在慢性肾脏病合并2型糖尿病患者中的适用性。

主要发现

  • 非奈利酮快速完全吸收,经肠壁和肝脏首过代谢,生物利用度43.5%,可与食物同服或不同服。
  • CYP3A4(90%)和CYP2C8(10%)参与非奈利酮广泛生物转化,代谢物无药理活性,经肾(80%)和胆道(20%)排泄。
  • 中重度肾损伤或中度肝损伤时非奈利酮AUC增加<40%。
  • CYP3A4活性调节剂影响非奈利酮暴露,与其敏感CYP3A4底物分类一致。
  • 非奈利酮对相关CYP酶和药物转运体无潜在影响。

关键数值与推荐

  • 中度或弱CYP3A4抑制剂或非奈利酮开始或调整剂量时,应监测血钾并适当调整非奈利酮剂量。
  • 强CYP3A4抑制剂与非奈利酮合用禁忌,应避免强或中度CYP3A4诱导剂。
  • 中度肝损伤患者应监测血钾并适当调整非奈利酮剂量。

临床怎么用

  • 起始非奈利酮前应测量血钾和肾功能,起始剂量取决于肾功能,后续根据血钾水平和肾功能变化调整剂量。
  • 合并使用中/弱CYP3A4抑制剂或调整其剂量时,需监测血钾并适当调整非奈利酮剂量。
  • 避免与强CYP3A4抑制剂合用,避免与强或中度CYP3A4诱导剂合用。
  • 中度肝损伤患者使用非奈利酮时应监测血钾并适当调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Finerenone, a selective and nonsteroidal antagonist of the mineralocorticoid receptor, has received regulatory approval with the indication of cardiorenal protection in patients with chronic kidney disease associated with type 2 diabetes. It is rapidly and completely absorbed and undergoes first-pass metabolism in the gut wall and liver resulting in a bioavailability of 43.5%. Finerenone can be taken with or without food. The pharmacokinetics of finerenone are linear and its half-life is 2 to 3 h in the dose range of up to 20 mg. Cytochrome P450 (CYP) 3A4 (90%) and CYP2C8 (10%) are involved in the extensive biotransformation of finerenone to pharmacologically inactive metabolites, which are excreted via both renal (80%) and biliary (20%) routes. Moderate or severe renal impairment, or moderate hepatic impairment result in area-under-the-curve increases of finerenone (< 40%), which do not require a dose adjustment per se, as the starting dose is based on estimated glomerular filtration rate (eGFR) and titrated according to serum potassium levels and eGFR decline. No relevant effects of age, sex, body size or ethnicity on systemic finerenone exposure were identified. Modulators of CYP3A4 activity were found to affect finerenone exposure, consistent with its classification as a sensitive CYP3A4 substrate. Serum potassium should be monitored during drug initiation or dosage adjustment of either a moderate or weak CYP3A4 inhibitor or finerenone, and the dose of finerenone should be adjusted as appropriate. Its use with strong inhibitors is contraindicated and strong or moderate inducers of CYP3A4 should be avoided. Finerenone has no potential to affect relevant CYP enzymes and drug transporters. Finerenone is a drug that is used to treat patients with chronic kidney disease and type 2 diabetes. Many of these patients take several medicines to treat other conditions. This review summarizes several studies showing the suitability of finerenone for these patients. Taken as a daily tablet, the dose circulates in the body before being quickly removed. The age, sex, body weight, and ethnicity of a patient do not affect dosing. As finerenone can cause an increase of serum potassium levels, potassium levels and kidney function should be measured before a patient starts treatment. The starting dose will depend on a patient’s kidney function, with the dose changed according to potassium levels and changes in kidney function. A protein called cytochrome P450 3A4 (CYP3A4) is key to removing finerenone from the body. Anyone taking medicines that strongly inhibit CYP3A4 should not take finerenone. Serum potassium levels should be measured before starting finerenone or changing the dose of either finerenone or ‘moderate’ or ‘weak’ CYP3A4 inhibitors, with the dose of finerenone adjusted as appropriate. Finerenone should not be taken alongside drugs that result in ‘moderate’ or ‘strong’ increases in CYP3A4 activity. In patients with moderate hepatic impairment, potassium should be monitored and finerenone doses be adjusted as appropriate. Finerenone is not expected to affect other drugs. Finerenone slows decline in kidney function, a treatment effect associated with reducing urine albumin. Potassium level-guided starting dose and dose changes support finerenone being effectively used and well tolerated in patients.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Heinig R, Eissing T. The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone. Clin Pharmacokinet. 2023. PMID: 37875671. doi:10.1007/s40262-023-01312-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。